Talk:Repotrectinib
Appearance
This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||
Pharmacology Mid‑importance | |||||||
|
WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine. | This article is within the scope of||
Mid | This article has been rated as Mid-importance on the project's importance scale. |
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Repotrectinib.
|
Article needs to be updated to reflect updated June 2024 FDA approval[edit]
The FDA has approved the drug in a new indication: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-repotrectinib-adult-and-pediatric-patients-ntrk-gene-fusion-positive. Someone with more medical knowledge than me should update the article. 60.250.123.226 (talk) 01:23, 14 June 2024 (UTC)